Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Cirrhosis

  Free Subscription


Articles published in Gastroenterology

Retrieve available abstracts of 59 articles:
HTML format



Single Articles


    October 2022
  1. AJMERA V, Kim BK, Yang K, Majzoub AM, et al
    Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.
    Gastroenterology. 2022;163:1079-1089.
    PubMed     Abstract available


    August 2022
  2. LO GH
    The beauty and sorrow of using PPI in patients with cirrhosis.
    Gastroenterology. 2022 Aug 3. pii: S0016-5085(22)00892.
    PubMed    


    June 2022
  3. KIM NJ, Vutien P, Berry K, Ioannou GN, et al
    Hepatocellular carcinoma risk declines but remains high enough for screening in the first 7 years after HCV cure with DAAs in patients with cirrhosis or high FIB-4.
    Gastroenterology. 2022 Jun 28. pii: S0016-5085(22)00681.
    PubMed    


  4. DUURSMA SS, Verkade HJ, Bodewes FAJA
    Cirrhosis and portal hypertension in compound heterozygous people with CF harboring one F508del CFTR gene mutation.
    Gastroenterology. 2022 Jun 10. pii: S0016-5085(22)00624.
    PubMed    


  5. SULLIVAN S, Jirapinyo P, Kumbhari V
    Clinical Care Pathway for the Risk Stratification and Management of Patients With Non-alcoholic Fatty Liver Disease.
    Gastroenterology. 2022;162:2131-2132.
    PubMed    


    May 2022
  6. WANG J, Liu D, Chen S
    Proton Pump Inhibitors for Patients with Cirrhosis: Good Medicine or Poison?
    Gastroenterology. 2022 May 17. pii: S0016-5085(22)00514.
    PubMed    


  7. SINGH SP
    Proton pump inhibitor increasing the risk of infection and mortality in cirrhosis- need closer look!
    Gastroenterology. 2022 May 2. pii: S0016-5085(22)00458.
    PubMed    


  8. GOUDSMIT BFJ, Putter H, Van Hoek B
    The Model for End-Stage Liver Disease 3.0: An Update Without Proven Accuracy.
    Gastroenterology. 2022;162:1781-1782.
    PubMed    


  9. GAN W, Liao B, Li X
    A Rare Cause of Liver Fibrosis in Adulthood.
    Gastroenterology. 2022;162:e1-e3.
    PubMed    


    April 2022
  10. CACCIOLA I
    Effects of PPIs in cirrhotic patients: What do we really know?
    Gastroenterology. 2022 Apr 29. pii: S0016-5085(22)00452.
    PubMed    


  11. MAHMUD N, Serper M, Taddei TH, Kaplan DE, et al
    The Association between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients with Cirrhosis: A Veterans Affairs Cohort Study.
    Gastroenterology. 2022 Apr 6. pii: S0016-5085(22)00352.
    PubMed     Abstract available


  12. QIAN T, Fujiwara N, Koneru B, Ono A, et al
    Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development.
    Gastroenterology. 2022;162:1210-1225.
    PubMed     Abstract available


    March 2022
  13. RUDNICK DA, Huang J, Hidvegi T, Chu AS, et al
    Regulation of PGC1alpha downstream of the insulin signaling pathway plays a role in the hepatic proteotoxicity of mutant alpha1-antitrypsin deficiency variant Z.
    Gastroenterology. 2022 Mar 14. pii: S0016-5085(22)00261.
    PubMed     Abstract available


    February 2022
  14. CARRIQUE L, Lynch J, Selzner N
    We thank Bekki et al and Bhagat et al for their comments on our article "Results of Early Transplantation for Alcohol-Related Cirrhosis: Integrated Addiction Treatment with Low Rate of Relapse". Bekki et al pointed out a trend toward inferior graft su
    Gastroenterology. 2022 Feb 3. pii: S0016-5085(22)00103.
    PubMed    


    December 2021
  15. YANG AH, Gandhi S, Urrunaga NH
    Liver Tumor post Liver Transplantation for Hepatitis C Cirrhosis: An Unusual Cause.
    Gastroenterology. 2021 Dec 26. pii: S0016-5085(21)04161.
    PubMed    


  16. KEFALAKES H
    DISPARITIES IN CIRRHOSIS MANAGEMENT OF BLACK PATIENTS: DO WE KNOW WHAT TO ADDRESS?
    Gastroenterology. 2021 Dec 1. pii: S0016-5085(21)03811.
    PubMed    


  17. SACK JS, Patel RS, Ahmad J
    Nausea and Vomiting 8 Months After Liver Transplantation.
    Gastroenterology. 2021;161:e12-e14.
    PubMed    


    November 2021
  18. BHAGAT N, Rathi S, Singh V
    Early Transplantation for Alcohol-Related Cirrhosis: Risks, Resources, and Relapse.
    Gastroenterology. 2021 Nov 5. pii: S0016-5085(21)03724.
    PubMed    


  19. VARGAS JF, Arab JP
    Pulsatile Epigastric Mass and Liver Masses in a 38-Year-Old Patient With Splenomegaly Since Childhood.
    Gastroenterology. 2021;161:e14-e16.
    PubMed    


    October 2021
  20. LEE TH, Roper J, King L
    MIRROR MIRROR ON THE WALL, WHO IS THE FITTEST OF THEM ALL: A NOVEL PREDICTION MODEL FOR POSTOPERATIVE HEPATIC DECOMPENSATION IN PATIENTS WITH CIRRHOSIS.
    Gastroenterology. 2021 Oct 21. pii: S0016-5085(21)03662.
    PubMed     Abstract available


    September 2021
  21. INTAGLIATA NM, Davitkov P, Allen AM, Falck-Ytter YT, et al
    AGA Technical Review on Coagulation in Cirrhosis.
    Gastroenterology. 2021 Sep 24. pii: S0016-5085(21)03477.
    PubMed    


  22. O'SHEA RS, Davitkov P, Ko CW, Rajasekhar A, et al
    AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis.
    Gastroenterology. 2021 Sep 24. pii: S0016-5085(21)03382.
    PubMed    


  23. BEKKI Y, Fenig Y
    Evaluation of Early Liver Transplantation for Alcohol-Related Cirrhosis.
    Gastroenterology. 2021 Sep 13. pii: S0016-5085(21)03491.
    PubMed    


    August 2021
  24. SU F
    COVID-19 and cirrhosis: a combination we must strive to prevent.
    Gastroenterology. 2021 Aug 25. pii: S0016-5085(21)03417.
    PubMed    


  25. CARRIQUE L, Quance J, Tan A, Abbey S, et al
    Results of Early Transplantation for Alcohol-Related Cirrhosis: Integrated Addiction Treatment with Low Rate of Relapse.
    Gastroenterology. 2021 Aug 6. pii: S0016-5085(21)03342.
    PubMed     Abstract available


    July 2021
  26. LOOMBA R, Mohseni R, Lucas KJ, Gutierrez JA, et al
    TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.
    Gastroenterology. 2021 Jul 20. pii: S0016-5085(21)03276.
    PubMed     Abstract available


  27. GE J, Pletcher MJ, Lai JC
    Outcomes of SARS-CoV-2 Infection in Patients with Chronic Liver Disease and Cirrhosis: a N3C Study.
    Gastroenterology. 2021 Jul 17. pii: S0016-5085(21)03244.
    PubMed     Abstract available


    June 2021
  28. CHIANG HC, Chien SC, Lin YJ
    Pleural effusion with gastric ulcer.
    Gastroenterology. 2021 Jun 26. pii: S0016-5085(21)03176.
    PubMed    


    May 2021
  29. EDWARDS LA, Goldenberg SD, Shawcross DL
    Meeting the challenge of antimicrobial resistance in cirrhosis: the invisible threat that lies within.
    Gastroenterology. 2021 May 25. pii: S0016-5085(21)03065.
    PubMed    


  30. GARCIA-TSAO G, Abraldes JG
    Non-selective beta-blockers in compensated cirrhosis: Preventing variceal hemorrhage or preventing decompensation?
    Gastroenterology. 2021 May 11. pii: S0016-5085(21)02972.
    PubMed    


    April 2021
  31. SHAMSADDINI A, Gillevet PM, Acharya C, Fagan A, et al
    Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients with Cirrhosis.
    Gastroenterology. 2021 Apr 12. pii: S0016-5085(21)00634.
    PubMed     Abstract available


    March 2021
  32. ASSELTA R, Paraboschi EM, Gerussi A, Cordell HJ, et al
    X chromosome contribution to the genetic architecture of primary biliary cholangitis.
    Gastroenterology. 2021 Mar 3. pii: S0016-5085(21)00466.
    PubMed     Abstract available


  33. ADENIJI N, Carr RM, Aby ES, Catana AM, et al
    Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities With Chronic Liver Diseases.
    Gastroenterology. 2021;160:1406-1409.
    PubMed    


  34. GOLDBERG D, Ross-Driscoll K, Lynch R
    County Differences in Liver Mortality in the United States: Impact of Sociodemographics, Disease Risk Factors, and Access to Care.
    Gastroenterology. 2021;160:1140-1150.
    PubMed     Abstract available


    February 2021
  35. YOUNOSSI ZM, Corey KE, Lim JK
    AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Gastroenterology. 2021;160:912-918.
    PubMed     Abstract available


    January 2021
  36. ROCKEY DC, Friedman SL
    Fibrosis regression after eradication of hepatitis C virus - from bench to bedside.
    Gastroenterology. 2021 Jan 30. pii: S0016-5085(21)00330.
    PubMed     Abstract available


  37. PAIK JM, Younossi Y, Henry L, Mishra A, et al
    Recent Trends in the Global Burden of Hepatitis B virus (HBV): 2007-2017.
    Gastroenterology. 2021 Jan 6. pii: S0016-5085(21)00029.
    PubMed    


    December 2020
  38. EMDIN CA, Haas M, Ajmera V, Simon TG, et al
    Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study.
    Gastroenterology. 2020 Dec 10. pii: S0016-5085(20)35545.
    PubMed     Abstract available


  39. YOUNOSSI ZM, Anstee QM, Wai-Sun Wong V, Trauner M, et al
    The Association of Histologic and Non-invasive Tests with Adverse Clinical and Patient-Reported Outcomes in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH).
    Gastroenterology. 2020 Dec 8. pii: S0016-5085(20)35529.
    PubMed     Abstract available


  40. ARVIND A, Osganian SA, Sjoquist JA, Corey KE, et al
    Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis.
    Gastroenterology. 2020;159:2232-2234.
    PubMed    


    November 2020
  41. HSU SJ, Zhang C, Jeong J, Lee SI, et al
    Enhanced meningeal lymphatic drainage ameliorates neuroinflammation and hepatic encephalopathy in cirrhotic rats.
    Gastroenterology. 2020 Nov 20. pii: S0016-5085(20)35439.
    PubMed     Abstract available


  42. NOUREDDIN M, Jones C, Alkhouri N, Gomez EV, et al
    Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.
    Gastroenterology. 2020;159:1985-1987.
    PubMed    


  43. LANG S, Demir M, Martin A, Jiang L, et al
    Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.
    Gastroenterology. 2020;159:1839-1852.
    PubMed     Abstract available


    October 2020
  44. ASEEM SO, Jalan-Sakrikar N, Chi C, Navarro-Corcuera A, et al
    Epigenomic Evaluation of Cholangiocyte TGFbeta Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis.
    Gastroenterology. 2020 Oct 12. pii: S0016-5085(20)35245.
    PubMed     Abstract available


  45. DE VRIES E, Bolier R, Goet J, Pares A, et al
    Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial.
    Gastroenterology. 2020 Oct 5. pii: S0016-5085(20)35226.
    PubMed     Abstract available


  46. ROMEO S
    MARC1 and HNRNPUL1: Two Novel Players in Alcohol-related Liver Disease.
    Gastroenterology. 2020;159:1231-1232.
    PubMed    


    August 2020
  47. HARRISON SA, Neff G, Guy CD, Bashir MR, et al
    Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
    Gastroenterology. 2020 Aug 8. pii: S0016-5085(20)35018.
    PubMed     Abstract available


  48. NABI O, Lacombe K, Boursier J, Mathurin P, et al
    Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study.
    Gastroenterology. 2020;159:791-793.
    PubMed    


  49. SCHNEIDER CV, Hamesch K, Gross A, Mandorfer M, et al
    Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi *Z Variant of AAT (Pi *MZ vs Pi *ZZ genotype) and Noncarriers.
    Gastroenterology. 2020;159:534-548.
    PubMed     Abstract available


  50. GUPTA V, Gupta I, Park J, Bram Y, et al
    Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells.
    Gastroenterology. 2020;159:624-638.
    PubMed     Abstract available


    June 2020
  51. LASSAILLY G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, et al
    Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.
    Gastroenterology. 2020 Jun 15. pii: S0016-5085(20)34758.
    PubMed     Abstract available


    May 2020
  52. TAYLOR RS, Taylor RJ, Bayliss S, Hagstrom H, et al
    Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Gastroenterology. 2020;158:1611-1625.
    PubMed     Abstract available


  53. SCORLETTI E, Afolabi PR, Miles EA, Smith DE, et al
    Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.
    Gastroenterology. 2020;158:1597-1610.
    PubMed     Abstract available


  54. GOLDNER D, Lavine JE
    Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.
    Gastroenterology. 2020;158:1967-1983.
    PubMed     Abstract available


  55. SCHWABE RF, Tabas I, Pajvani UB
    Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.
    Gastroenterology. 2020;158:1913-1928.
    PubMed     Abstract available


    March 2020
  56. SAHIN-TOTH M
    Channelopathy of the pancreas causes chronic pancreatitis.
    Gastroenterology. 2020 Mar 20. pii: S0016-5085(20)30376.
    PubMed    


  57. MEJIAS M, Gallego J, Naranjo-Suarez S, Ramirez M, et al
    CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis.
    Gastroenterology. 2020 Mar 10. pii: S0016-5085(20)30328.
    PubMed     Abstract available


    January 2020
  58. LIU X, Xu J, Rosenthal S, Zhang LJ, et al
    Identification of Lineage-specific Transcription Factors That Prevent Activation of Hepatic Stellate Cells and Promote Fibrosis Resolution.
    Gastroenterology. 2020 Jan 20. pii: S0016-5085(20)30117.
    PubMed     Abstract available


  59. LIN YH, Zhang S, Zhu M, Lu T, et al
    Mice With Increased Numbers of Polyploid Hepatocytes Maintain Regenerative Capacity but Develop Fewer Tumors Following Chronic Liver Injury.
    Gastroenterology. 2020 Jan 20. pii: S0016-5085(20)30116.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: